Fuji Pharma Co., Ltd.
Fuji Pharma Co., Ltd. Financial Summary for the Fiscal Year Ended September 2026 [Japanese GAAP] (Consolidated) [Latest]
Consolidated revenue for the fiscal year ended September 2026 increased to the 62,386 million yen range (62,386 million yen, +20.7% YoY). Operating income was 6,355 million yen (+27.4%), ordinary income was 6,176 million yen (+38.5%), but net income attributable to owners of parent decreased to 2,831 million yen (-5.6%). Forecasts for the next fiscal year are revenue of 69,190 million yen (+10.9%), operating income of 7,420 million yen (+16.8%), and net income of 4,880 million yen (+72.4%). Dividends are planned at 23 yen interim and 29 yen year-end, totaling 52 yen, continuing a progressive dividend policy targeting a payout ratio of 30% or more.
Key Figures
- Revenue: 62,386 million yen (YoY +20.7%)
- Operating Income: 6,355 million yen (YoY +27.4%)
- Net Income Attributable to Owners of Parent: 2,831 million yen (YoY -5.6%)
AI要約
Performance Overview
The Fuji Pharma Co., Ltd. Group is promoting its medium-term management plan under the "Long-term Vision 2035," positioning four areas—women's healthcare, biosimilars, global CMO, and one other growth area—as growth drivers. Consolidated revenue for the fiscal year ended September 2026 was 62,386 million yen, a substantial increase year-on-year. Operating income was 6,355 million yen and ordinary income was 6,176 million yen, both marking significant increases. However, due to impairment losses on investment securities and impairments of long-term prepayments, net income attributable to owners of parent declined to 2,831 million yen compared with the prior year. For the next fiscal year, the Company forecasts revenue of 69,190 million yen, operating income of 7,420 million yen, and net income of 4,880 million yen, expecting profit growth.
Dividends, Financial Position and Outlook
The dividend policy remains progressive; for this fiscal year, an interim dividend of 23 yen and a year-end dividend of 29 yen are planned, totaling 52 yen. While the medium-term plan anticipates increased R&D spending, the Company intends to secure profits through expense management. The financial position shows total assets of 98,287 million yen, net assets of 52,451 million yen, and an equity ratio of 53.4%. Cash flows are: operating CF 6,174 million yen, investing CF -3,630 million yen, financing CF -429 million yen, and cash and cash equivalents of 9,496 million yen.
Revenue Trend
Operating Income Trend
Ordinary Income Trend
Net Income Attributable to Owners of Parent Trend
Net Assets per Share
Fuji Pharma Co., Ltd.
Company overview · Stock price · Financial data · All IR